Evidence map›Paper›PMID 39511630›Full record

ArticleJournal of translational medicine2024

Letter: The risk-benefit balance of CRISPR-Cas screening systems in gene editing and targeted cancer therapy.

Qiang Yi, Xinting Ouyang, Gangfeng Zhu, Jinghua Zhong

Abstract readLetter
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of translational medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Qiang YiThe First Clinical Medical College, Gannan Medical University,Jiangxi Provincial Tumor Clinical Key Specialty, Jiangxi Provincial Malignant Tumor Clinical Medical Research Center, Ganzhou, 341000, Jiangxi Province, China.
Xinting OuyangThe First Clinical Medical College, Gannan Medical University,Jiangxi Provincial Tumor Clinical Key Specialty, Jiangxi Provincial Malignant Tumor Clinical Medical Research Center, Ganzhou, 341000, Jiangxi Province, China.
Gangfeng ZhuThe First Clinical Medical College, Gannan Medical University,Jiangxi Provincial Tumor Clinical Key Specialty, Jiangxi Provincial Malignant Tumor Clinical Medical Research Center, Ganzhou, 341000, Jiangxi Province, China.
Jinghua ZhongDepartment of Oncology, The First Affiliated Hospital of Gannan Medical University,Jiangxi Provincial Tumor Clinical Key Specialty, Jiangxi Provincial Malignant Tumor Clinical Medical Research Center, 128 Jinling Road, Ganzhou, 341000, Jiangxi Province, China. m18770738786@163.com.

Funding

National Natural Science Foundation of China 82260604Natural Science Foundation of Jiangxi Province 20192BAB205053
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID39511630
PMCPMC11545896

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.